Cargando…

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report

BACKGROUND: Extensive disease of cholangiocarcinoma (CC) determines the overall outcome and limits curative resection. Despite chemotherapy, which has been introduced to improve the outcome of biliary tract malignancies, the benefit in survival is still marginal. CASE PRESENTATION: We report a 69-ye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sprinzl, Martin F, Schimanski, Carl C, Moehler, Markus, Schadmand-Fischer, Simin, Galle, Peter R, Kanzler, Stephan
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564184/ https://www.ncbi.nlm.nih.gov/pubmed/16846514 http://dx.doi.org/10.1186/1471-2407-6-190

Ejemplares similares

Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas
por: Sprinzl, Martin F., et al.
Publicado: (2008)

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective
por: Wehler, Thomas C., et al.
Publicado: (2013)

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective
por: Wehler, Thomas C., et al.
Publicado: (2013)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy
por: Wehler, Thomas C., et al.
Publicado: (2012)

Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma
por: Gockel, Ines, et al.
Publicado: (2006)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Strong Expression of Chemokine Receptor CXCR4 by Renal Cell Carcinoma Correlates with Advanced Disease
por: Wehler, Thomas C., et al.
Publicado: (2008)

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases
por: Desuki, Alexander, et al.
Publicado: (2019)

Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma
por: Cho, Seulki, et al.
Publicado: (2017)

Reversal of Jaundice in Two Patients with Inoperable Cholangiocarcinoma Treated with Cisplatin and Gemcitabine Combination
por: Criel, Maarten, et al.
Publicado: (2012)

Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
por: Inoue, Tadahisa, et al.
Publicado: (2022)

Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer
por: Fiore, Michele, et al.
Publicado: (2015)

Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study
por: Sgourakis, George, et al.
Publicado: (2012)

(111)In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma
por: Shih, Ying-Hsia, et al.
Publicado: (2015)

Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells
por: Heinrich, Bernd, et al.
Publicado: (2013)

Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma
por: Zheng, Wen-Heng, et al.
Publicado: (2019)

Photochemical internalization and gemcitabine combined with first-line chemotherapy in perihilar cholangiocarcinoma: observations in three patients
por: Dechêne, Alexander, et al.
Publicado: (2020)

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
por: Moehler, Markus, et al.
Publicado: (2016)

Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma
por: Suksawat, Manida, et al.
Publicado: (2022)

Local signaling by the EGF receptor
por: Kempiak, Stephan J., et al.
Publicado: (2003)

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction
por: Moehler, Markus, et al.
Publicado: (2013)

Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy
por: Pietropaolo, Giuseppe, et al.
Publicado: (2020)

Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?: Case Series
por: Kang, Myoung Hee, et al.
Publicado: (2014)

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
por: Gairing, Simon Johannes, et al.
Publicado: (2021)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
por: Heinrich, Stefan, et al.
Publicado: (2011)

Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway
por: Son, Dong Ju, et al.
Publicado: (2015)

Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma
por: Trojan, Jörg, et al.
Publicado: (2022)

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
por: Trarbach, T, et al.
Publicado: (2010)

Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial
por: Li, Hao, et al.
Publicado: (2016)

Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report
por: Higer, Maximilian, et al.
Publicado: (2020)

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4
por: Schimanski, C C, et al.
Publicado: (2006)

Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
por: Zhao, Jemmy, et al.
Publicado: (2023)

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
por: Evans, Rachel, et al.
Publicado: (2022)

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines
por: Solmi, Rossella, et al.
Publicado: (2008)

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
por: Moehler, Markus, et al.
Publicado: (2019)

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
por: Varamo, Chiara, et al.
Publicado: (2019)

LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma
por: Shen, Sheng, et al.
Publicado: (2019)

Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro
por: Fan, Shanshan, et al.
Publicado: (2021)

Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5b1sh0ie2uedhuaqg78c4scg0b